Cholesterol synthesis is increased in mixed hyperlipidaemia

Biochimica et Biophysica Acta - Lipids and Lipid Metabolism

Volumn 1394, Issue 2-3, 1998, Pages 146-152

  Naoumova, R P ^a   Kim, K D ^a   Neuwirth, C ^a   Niththyananthan, S ^a   Rendell, N B ^b   Taylor, G W ^b   Thompson, G R ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Apolipoprotein B; HMG CoA reductase; Mevalonate

Indexed keywords

CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVALONIC ACID; TRIACYLGLYCEROL;

ARTICLE; BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; FEMALE; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; APOLIPOPROTEINS E; CHOLESTEROL; CHOLESTEROL, LDL; FASTING; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYPERLIPIDEMIAS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MEVALONIC ACID; PHENOTYPE; TRIGLYCERIDES;

EID: 0031761030     PISSN: 00052760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0005-2760(98)00103-9     Document Type: Article

References (49)

1. Gibbons G.F. Assembly and secretion of hepatic very-low-density lipoprotein. Biochem. J. 268:1990;1-13.
2. Dixon J.L., Ginsberg H.N. Regulation of hepatic secretion of apolipoprotein B-containing lipoproteins: information obtained from cultured liver cells. J. Lipid Res. 13:1993;629-636.
3. Yao Z., McLeod R.S. Synthesis and secretion of hepatic apolipoprotein B-containing lipoproteins. Biochem. Biophys. Acta. 1212:1994;152-166.
4. Thompson G.R., Naoumova R.P., Watts G.F. Role of cholesterol in regulating apolipoprotein B secretion by the liver. J. Lipid Res. 37:1996;439-447.
5. Sniderman A.D., Cianflone K. Substrate delivery as a determinant of hepatic apoB secretion. Arterioscler. Thromb. 13:1993;629-636.
6. White A.L., Graham D.L., LeGros J., Pease R.J., Scott J. Oleate-mediated stimulation of apolipoprotein B secretion from rat hepatoma cells. J. Biol. Chem. 267:1992;5080-5086.
7. Parker T.S., McNamara D.J., Brown C.D., Kolb E., Ahrens H., Alberts A.W., Tobert J., Chen J., de Schepper P.J. Plasma mevalonate as a measure of cholesterol synthesis in man. J. Clin. Invest. 74:1984;795-804.
8. Cummings M.H., Watts G.F., Pal C., Umpleby M., Hennessy T.R., Naoumova R., Sönksen P.H. Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in obesity: a stable isotope study. Clin. Sci. 88:1995;225-233.
9. Cummings M.H., Watts G.F., Umpleby A.M., Hennessy T.R., Naoumova R., Slavin B.M., Thompson G.R., Sönksen P.H. Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-00 in NIDDM. Diabetologia. 38:1995;959-967.
10. Watts G.F., Naoumova R., Cummings M.H., Umpleby A.M., Slavin B.M., Sönksen P.H., Thompson G.R. Direct correlation between cholesterol synthesis and hepatic secretion of apolipoprotein B-00 in normolipidaemic subjects. Metabolism. 44:1995;1052-1057.
11. Watts G.F., Cummings M.H., Umpleby M., Quiney J.R., Naoumova R., Thompson G.R., Sönksen P.H. Simvastatin decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-00 in heterozygous familial hypercholesterolaemia: pathophysiological and therapeutic implications. Eur. J. Clin. Invest. 25:1995;559-567.
12. Watts G.F., Naoumova R.P., Kelly J.M., Riches F.M., Croft K.D., Thompson G.R. Inhibition of cholesterogenesis decreases hepatic secretion of apoB-00 in normolipidemic subjects. Am. J. Physiol. 273 (Endocrinol. Metab. 36):1997;E462-E470.
13. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18:1972;499-502.
14. Naoumova R.P., Marais A.D., Mountney J., Firth J.C., Rendell N.B., Taylor G.W., Thompson G.R. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia. Atherosclerosis. 119:1996;203-213.
15. McDowell I.F., Wisdom G.B., Trimble E.R. Apolipoprotein E phenotype determined by agarose gel electrofocusing and immunoblotting. Clin. Chem. 35:1989;2070-2073.
16. Pappu A.S., Illingworth D.R. Contrasting effects of lovastatin and cholestyramine on low-density cholesterol and 24-h urinary mevalonate excretion in patients with heterozygous familial hypercholesterolaemia. J. Lab. Clin. Med. 4:1989;554-562.
17. Parker T.S., McNamara D.J., Brown C., Garrigan D., Kolb R., Batwin H., Ahrens E.H. Jr. Mevalonic acid in human plasma: relationship of concentration and circadian rhythm to cholesterol synthesis rates in man. Proc. Natl Acad. Sci. USA. 79:1982;3037-3041.
18. Jones P.J.H., Pappu A.S., Illingworth D.R., Leitch C.A. Correspondence between plasma mevalonic acid levels and deuterium uptake in measuring human cholesterol synthesis. Eur. J. Clin. Invest. 22:1992;609-613.
19. Lindenthal B., Simatupag A., Dotti M.T., Federico A., Lütjohann D., von Bergmann K. Urinary excretion of mevalonic acid as an indicator of cholesterol synthesis. J. Lipid Res. 37:1996;2193-2201.
20. Yoshida T., Houda A., Tanaka N., Matsuzaki Y., He B., Osuga T., Kobajashi N., Ozawa K., Miyazaki H. Simultaneous determination of mevalonate and 7α-hydroxy-cholesterol in human plasma by gas chromatography-mass spectrometry as indices of cholesterol and bile acid biosynthesis. J. Chromatogr. 613:1993;185-193.
21. Illingworth D.R., Bacon S., Pappu A.S., Secton G.J. Comparative hypolipidemic effects of lovastatin and simvastatin in patients with heterozygous familial hypercholesterolemia. Atherosclerosis. 96:1992;53-64.
22. Naoumova R.P., Dunn S., Rallidis L., Abu-Muhana O., Neuwirth C., Rendell N.B., Taylor G.W., Thompson G.R. Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin. J. Lipid Res. 38:1997;1496-1500.
23. Naoumova R.P., Marais D., Firth J.C., Neuwirth C.K.Y., Taylor G.W., Thompson G.R. Atorvastatin augments therapy of homozygous familial hypercholesterolemia by inhibiting up-regulation of cholesterol synthesis after apheresis and bile acid sequestrants. Circulation. 94:1996;I-583.
24. Pfohl M., Naoumova R.P., Neuwirth C., Sussekov A., Smykowski J., Rendell N.G., Taylor G.W., Seif F.J., Thompson G.R. Upregulation of cholesterol synthesis after acute reduction of low density lipoprotein by apheresis in normocholesterolaemic subjects: evidence for a threshold effect. Atherosclerosis. 35:1997;257-262.
25. Pfohl M., Naoumova R.P., Kim K.D., Thompson G.R. Use of cholesterol precursors to assess changes in cholesterol synthesis under non-steady state conditions. Eur. J. Clin. Invest. 6:1998;491-496.
26. Pfohl M., Naoumova R.P., Klass C., Knisel W., Jakober B., Risler T., Thompson G.R. Acute and chronic effects on cholesterol biosynthesis of LDL-apheresis with or without concomitant HMG-CoA reductase inhibitor therapy. J. Lipid Res. 35:1994;1946-1955.
27. G.R. Thompson. A handbook of hyperlipidaemia, revised edition, Current Science, London, 1994.
28. Huff M.W., Burnett J.R. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and hepatic apolipoprotein B secretion. Curr. Opin. Lipidol. 8:1997;138-145.
29. Cianflone K.M., Yasrud Z., Rodriguez M.A., Vos D., Sniderman A.D. Regulation of apoB secretion from HepG2 cells: evidence for a critical role for cholesterol ester synthesis in the response to a fatty acid challenge. J. Lipid Res. 31:1990;2045-2055.
30. Dashti N. The effect of low density lipoproteins, cholesterol, and 25-hydroxycholesterol on apolipoproteinB gene expression in HepG2 cells. J. Biol. Chem. 267:1992;7160-7169.
31. Huff M.W., Telford D.E., Barrett P.H.R., Bilheimer J.T., Gillies P.J. Inhibition of hepatic ACAT decreases apoB secretion in miniature pigs fed a cholesterol-free diet. Arterioscler. Thromb. 14:1994;498-508.
32. Tanaka M., Jingami H., Otani H., Cho M., Ueda Y., Arai H., Nagano Y., Doi T., Yokode M., Kita T. Regulation of apolipoprotein B production and secretion in response to the change of intracellular cholesteryl ester content in rabbit hepatocytes. J. Biol. Chem. 268:1993;12713-12718.
33. Burnett J.R., Wilcox L.J., Telford D.E., Kleinstiver S.J., Barrett P.H.R., Newton R.S., Huff M.W. Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs. Arterioscler. Thromb. Vasc. Biol. 17:1997;2589-2600.
34. Benoist F., Grand-Perret T. ApoB-00 secretion by HepG2 cells is regulated by the rate of triglyceride biosynthesis but not by intracellular lipid pools. Arterioscler. Thromb. Vasc. Biol. 16:1996;1229-1235.
35. Wu X., Sakata N., Lui E., Ginsberg H.N. Evidence for a lack of regulation of the assembly and secretion of apolipoprotein B-containing lipoprotein from HepG2 cells by cholesteryl esters. J. Biol. Chem. 269:1994;12375-12382.
36. Lewis G.F., Uffelman K.D., Szeto L.W., Steiner G. The effects of acute hyperinsulinemia on very low density lipoprotein (VLDL) triglyceride and VLDL apolipoprotein (apo) B production in normal weight and obese individuals. Diabetes. 42:1993;833-842.
37. Scoppola A., Testa G., Frontoni S., Maddaloni E., Gambardella S., Menzinger G., Lala A. Effects of insulin on cholesterol synthesis in type II diabetes patients. Diabetes Care. 18:1995;1362-1369.
38. Naoumova R.P., Cummings M.H., Watts G.F., Rendell N.B., Taylor G.W., Sönksen P.H., Thompson G.R. Acute hyperinsulinaemia decreases cholesterol synthesis less in subjects with non-insulin-dependent diabetes mellitus than in non-diabetic subjects. Eur. J. Clin. Invest. 26:1996;332-340.
39. Sparks J.D., Sparks C.E. Hormonal regulation of lipoprotein assembly and secretion. Curr. Opin. Lipidol. 4:1993;177-186.
40. Pullinger C.R., North J.D., Teng B.-B., Rifici V.A., de Brito A.E.R., Scott J. The apolipoprotein B gene is constitutively expressed in HepG2 cells: regulation of secretion by oleic acid, albumin, and insulin, and measurement of the mRNA half-life. J. Lipid Res. 30:1989;1065-1077.
41. Verkade H.J., Fast D.G., Rusinol A.E., Scraba D.G., Vance D.E. Impaired biosynthesis of phosphatidylcholine causes a decrease in the number of very low density lipoprotein particles in the Golgi but not in the endoplasmic reticulum of rat liver. J. Biol. Chem. 268:1993;24990-24996.
42. Cabezas M.C., de Bruin T.W.A., de Valk H.W., Shoulders C.C., Jansen H., Erkelens D.W. Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance. J. Clin. Invest. 92:1993;160-168.
43. Kempen H.J.M., Gevers Leuven J.A., von der Voort H.A., de Knijff P., Havekes L. Lathosterol level in plasma is elevated in type III hyperlipidaemia, but not in non-type III subjects with apolipoprotein E2/2 phenotype nor in type IIa or IIb hyperlipoproteinemia. Metabolism. 40:1991;231-235.
44. A. Asplund-Carlson, E. Lund, I. Björkhem, L.A. Carlson, Studies in hypertriglyceridaemia VI: serum lathosterol concentration raised in hypertriglyceridaemic non-diabetic men with hyperinsulinaemia, J. Intern. Med., in press.
45. Cummings M.H., Watts G.F. Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in cholesteryl ester storage disease. Clin. Chem. 4:1995;111-114.
46. Ginsberg H.N., Le N.-A., Short N., Ramakrishnan R., Desnick R.J. Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. J. Clin. Invest. 80:1987;1692-1697.
47. Kesaniemi Y.A., Ehnholm C., Miettinen T.A. Intestinal cholesterol absorption efficiency in man is related to apoprotein E phenotype. J. Clin. Invest. 80:1987;578-5581.
48. Carmena R., Roederer G., Mailloux H., Lussier-Cacan S., Davignon J. The response to lovastatin treatment in patients with heterozygous familial hypercholesterolaemia is modulated by apolipoprotein E polymorphism. Metabolism. 42:1993;895-901.
49. J. Pedro-Botet, R. Ordovas, R. Baker-Arkema, D. Black, E. Stein, E. Schaefer, Effect of apolipoprotein E genotype on low-density lipoprotein cholesterol response to atorvastatin therapy, XII International Symposium on Drugs Affecting Lipid Metabolism, Florence, May 30-June 3, 1998, Abstracts, p. 26.